Speaker: Dr. Sébastien Baillieul & Dr. Frédéric Gagnadoux

This webinar, featuring Prof. Frédéric Gagnadoux and Dr. Sébastien Baillieul, explores the move toward personalized medicine in Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS). The speakers emphasize moving beyond the traditional Apnea-Hypopnea Index (AHI) to identify clinical phenotypes and endotypes for better risk stratification and treatment selection. Four major clinical phenotypes are highlighted: the sleepy phenotype, COMISA (comorbid insomnia and sleep apnea), the metabolic phenotype, and the comorbid/asymptomatic phenotype. The sleepy phenotype is identified as particularly vulnerable to cardiovascular risk but also responds well to CPAP. New biomarkers such as hypoxic burden, delta heart rate, and pulse wave amplitude drop are introduced to improve risk prediction and personalized treatment, especially for patients with residual sleepiness or poor CPAP adherence. The webinar concludes by discussing future directions including pharmacotherapy (e.g., dual agonists for weight loss) and endotype-based therapies.

Long Summary

This BMC Learning Center webinar, titled "Endophenotypic Characterization of OSAHS and its Therapeutic Implications," features Prof. Frédéric Gagnadoux and Dr. Sébastien Baillieul. The central theme is the shift from a one-size-fits-all approach in obstructive sleep apnea treatment toward personalized medicine based on detailed phenotyping, biomarkers, and endotyping.